Market capitalization | CHF1.94b |
Enterprise Value | CHF-296.42m |
P/E (TTM) P/E ratio | 15.45 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | -5.57 |
P/S ratio (TTM) P/S ratio | 36.39 |
P/B ratio (TTM) P/B ratio | 0.87 |
Dividend yield | 5.67% |
Last dividend (FY23) | CHF2.00 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a BB Biotech forecast:
2 Analysts have issued a BB Biotech forecast:
Sep '24 |
+/-
%
|
||
Revenue | 53 53 |
1,697%
1,697%
|
|
Gross Profit | 47 47 |
669%
669%
|
|
EBITDA | 126 126 |
136%
136%
|
EBIT (Operating Income) EBIT | 126 126 |
136%
136%
|
Net Profit | 125 125 |
136%
136%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BB Biotech AG is a closed-end investment fund, which engages in investing in biotechnology companies. It focuses on the development and commercialization of novel drugs sectors. The company was founded on November 9, 1993 and is headquartered in Schaffhausen, Switzerland.
Head office | Switzerland |
Founded | 1993 |
Website | www.bbbiotech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.